A new hire's right to buy 8,400 Akebia shares phases in over four years, if they stay.
Akebia Therapeutics (AKBA) granted a new employee options to purchase 8,400 common shares at an exercise price of $0.92 per share. These options, issued as an employment inducement, vest over four years with a 10-year term, subject to the employee's continued service. The grant aligns with Nasdaq Listing Rule 5635(c)(4).
Long term debt to total equity ratio of Akebia Therapeutics, Inc. – HAN:AX9
This article displays financial information for Akebia Therapeutics, Inc. (AX9) on the Hannover Stock Exchange, specifically focusing on its long-term debt to total equity ratio. It is a data-oriented page from TradingView, indicating that the market for this stock is currently closed with no trades.
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced it will release its third-quarter 2023 financial results on Wednesday, November 8, 2023, before the market opens. The company will also host a conference call on the same day at 8:00 a.m. ET to discuss these results and recent business highlights. Interested parties can access the call via a registration link or a live webcast on Akebia's investor relations website.
Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp
State Street Corp significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) by 53.6% in the second quarter, selling over 6.2 million shares. Despite this, other institutional investors have either increased or initiated positions in the biopharmaceutical company. Akebia Therapeutics reported better-than-expected Q2 earnings and revenue, with its lead product Vafseo approved for anemia associated with chronic kidney disease in dialysis patients.
One trial, three rare kidney diseases: Akebia doses its first patient
Akebia Therapeutics (AKBA) has dosed the first patient in its Phase 2 basket trial for investigational drug ebribafusp, targeting rare complement-mediated kidney diseases like IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The study plans to enroll up to 30 patients, with initial data expected in 2027. Ebribafusp is designed to inhibit complement activation locally in kidney tissue without affecting the systemic complement system, potentially offering a safer long-term treatment option.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics has announced that the first patient has been dosed in its Phase 2 basket trial for ebribafusp, an investigational treatment for rare complement-mediated kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is designed to inhibit complement activation directly in kidney tissue, aiming to provide a long-term treatment option with reduced infection risk compared to systemic inhibition. Initial data from this open-label trial, which will evaluate the safety, efficacy, and pharmacokinetics of the drug in up to 30 patients, is expected in 2027.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics has announced that the first patient has been dosed in its Phase 2 basket trial for ebribafusp, an investigational treatment for rare complement-mediated kidney diseases like IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is designed to inhibit complement activation directly in kidney tissue without affecting the complement system in the blood, potentially offering a long-term treatment option with reduced infection risk. Initial data from this open-label trial, which will evaluate safety, efficacy, and pharmacokinetics in up to 30 patients, is expected in 2027.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics has dosed the first patient in its Phase 2 basket trial for ebribafusp, an investigational treatment for rare complement-mediated kidney diseases like IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is designed to specifically inhibit complement activation in kidney tissues without affecting the systemic complement system, aiming to offer a long-term treatment option with reduced infection risk. Initial data from the open-label trial, which will enroll up to 30 patients, is anticipated in 2027.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics announced that the first patient has been dosed in its Phase 2 basket trial for ebribafusp, an investigational treatment for rare complement-mediated kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Ebribafusp is designed to inhibit complement activation directly in kidney tissue without suppressing the systemic complement system, potentially offering a safer long-term treatment option. Initial data from this open-label trial, which will enroll up to 30 patients, is expected in 2027.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics has announced the first patient has been dosed in its Phase 2 basket trial for ebribafusp, an investigational anti-C3d factor H fusion protein. The trial will evaluate ebribafusp for the treatment of rare complement-mediated kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy, with initial data expected in 2027. The drug is designed to inhibit complement activation directly in kidney tissue, potentially offering a long-term treatment option with reduced infection risk.
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen has upgraded Akebia Therapeutics (NASDAQ:AKBA) from a "sell" to a "hold" rating. This aligns with MarketBeat's consensus "Hold" rating, which includes four Buy, two Hold, and one Sell rating, with an average price target of $3.90. The company's stock is currently trading near its 52-week low, despite beating analyst expectations for its last quarterly revenue and adjusted EPS.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by Brokerages
Akebia Therapeutics (NASDAQ:AKBA) has received an average "Hold" recommendation from seven brokerages, with an average 12-month price target of $3.90. The stock recently opened at $0.95, near its 12-month low, and institutional investors hold 33.92% of the shares. The company reported better-than-expected quarterly earnings and revenue, but a CFO recently sold shares to cover tax obligations.
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital
Westpark Capital initiated coverage on Akebia Therapeutics (NASDAQ:AKBA) with a "buy" rating and a $4.50 price target, suggesting a significant upside. Despite this, the consensus rating from analysts remains "Hold" with an average target price of $3.90, reflecting mixed sentiment. The biopharmaceutical company recently reported better-than-expected quarterly revenue of $49.13 million and a narrower loss of $0.02 per share.
BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA
BlackRock Inc. has acquired 19,986,374 shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), representing approximately 7.45% of the company and valued at $22.78 million. Other institutional investors have also adjusted their holdings, with institutional ownership collectively reaching 33.92%. Akebia Therapeutics reported a narrower-than-expected quarterly loss and slightly exceeded revenue estimates, though it remains unprofitable with a negative net margin.
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Akebia Therapeutics announced that its CEO and CFO/CBO will participate in one-on-one investor meetings at the Wells Fargo Healthcare Conference in Boston from September 8-10, 2026. Management plans to discuss the company's commercial products and its pipeline of kidney disease programs. Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of individuals with kidney disease.
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Akebia Therapeutics announced that its CEO, John P. Butler, and CFO/CBO, Erik Ostrowski, will participate in one-on-one investor meetings at the 2026 Wells Fargo Healthcare Conference in Boston from September 8-10, 2026. Management will discuss the company's commercial products and its clinical-stage pipeline focused on kidney disease programs. Akebia Therapeutics is a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease.
Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA
Nantahala Capital Management LLC has acquired 2 million shares of Akebia Therapeutics (NASDAQ:AKBA) worth approximately $2.28 million, representing a 0.72% stake. Other institutional investors like BlackRock Inc., UBS Group AG, and Goldman Sachs Group Inc. have also significantly increased their holdings. Analyst sentiment for Akebia Therapeutics is mixed, with a consensus "Hold" rating and an average price target of $3.75, following the company beating its quarterly earnings estimates with a reported loss of $0.02 per share against an estimated $0.04 loss.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts
Six research firms have given Akebia Therapeutics (NASDAQ:AKBA) an average rating of "Hold", with a consensus 12-month target price of $3.75. Recent analyst reports show mixed sentiment, including upgrades, downgrades, and reiterations of "buy" and "sell" ratings. The company recently reported better-than-expected earnings and revenue for the last quarter.
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4
Piper Sandler has reiterated its Buy rating on Akebia Therapeutics (AKBA.US) and maintained its target price at $4. This indicates continued confidence from the analyst firm in the company's prospects.
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC significantly reduced its stake in Akebia Therapeutics (NASDAQ:AKBA) during the first quarter, selling 1.76 million shares and retaining 1.83 million, now valued at $2.55 million. Despite this, Akebia reported stronger-than-expected quarterly revenues of $49.13 million and a smaller loss per share of $0.02, surpassing analyst estimates. The stock, currently trading near its 52-week low, holds an average "Hold" rating from analysts with a consensus price target of $3.75, while institutional investors collectively own 33.92% of the company.
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings
HC Wainwright has revised its FY2026 earnings estimate for Akebia Therapeutics (NASDAQ:AKBA) to a loss of $0.12 per share, down from a previous estimate of $0.08, while maintaining a "Buy" rating. Despite this negative revision, Akebia recently exceeded expectations in its latest quarterly results, reporting a $0.02-per-share loss against a projected $0.04 loss and higher-than-expected revenue. The stock currently holds a consensus "Hold" rating with a target price of $3.75, trading near its 52-week low.
Akebia Therapeutics (AKBA) AGM 2026 Summary
This article summarizes Akebia Therapeutics' (AKBA) 2026 Annual General Meeting (AGM), detailing the agenda, including the election of Class III directors, approval of an increase in authorized capital, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. It also outlines the voting outcomes, confirming the election of directors, approval of share authorization, passing of executive compensation, and ratification of the auditor. The summary also includes a list of recent company events and their financial highlights.
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform"
Leerink Partners has downgraded Akebia Therapeutics (NASDAQ:AKBA) from "Outperform" to "Market Perform," setting a new price target of $1.00. This downgrade implies a potential upside of 4.78% from its previous close. Despite beating quarterly EPS and revenue estimates, Akebia's shares fell 26%, opening at $0.95, indicating mixed analyst sentiment with a consensus "Hold" rating and an average target price of $3.75.
Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts
Akebia Therapeutics (AKBA) stock fell 26% to US$0.95 following a Q2 2026 earnings report showing revenue decline and a net loss, raising concerns about its valuation. While the company's Vafseo product is showing strong growth, the overall revenue fall and decline in Auryxia sales, coupled with ongoing funding needs, present a challenging outlook for investors. The market is questioning whether its low price-to-sales ratio reflects a deep value opportunity or simply its persistent losses and dilution risks.
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics reported its second-quarter earnings, highlighting significant revenue growth for its Vafseo anemia treatment and positive interim results from the VOICE study, which met its stopping criteria for non-inferiority and superiority. The company also detailed advancements in its rare kidney disease pipeline with ebribafusp and praliciguat, and provided financial updates, including a net loss of $8.9 million and expectations for Vafseo's pricing post-TDAPA period.
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has initiated a Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to assess the safety, efficacy, and pharmacokinetics of weekly subcutaneous dosing, focusing on reducing complement activation in the kidney without affecting the blood complement system. Initial data from the open-label study, involving up to 30 patients, is expected in 2027.
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics (NASDAQ: AKBA) reported its Q2 2026 earnings, highlighting a significant 60% year-over-year increase in Vafseo revenue to $21.3 million, driven by over 10,500 active patients. The company also announced that its VOICE trial for Vafseo met its interim stopping criteria, demonstrating a statistically significant reduction in mortality and hospitalization. Despite these successes, total revenue declined to $49.1 million due to generic competition impacting Auryxia sales, and the company anticipates a potential decline in Vafseo revenue in 2027 due to pricing reductions after its TDAPA period ends.
Transcript : Akebia Therapeutics, Inc., Q2 2026 Earnings Call, Aug 05, 2026
This article is a transcript of Akebia Therapeutics, Inc.'s Q2 2026 Earnings Call held on August 5, 2026. The content provides details from the call, including an operator's message, but the full transcript is reserved for subscribers. It also lists recent news and financial performance data for Akebia Therapeutics (AKBA).
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics announced strong second-quarter 2026 financial results, with Vafseo net product revenues growing to $21.3 million and over 10,500 patients on therapy. The company also highlighted significant advancements in its rare kidney disease pipeline, including the initiation of a Phase 2 trial for ebribafusp and positive interim analysis from the VOICE trial demonstrating improved safety outcomes for Vafseo. Despite a net loss due to decreased Auryxia revenues and increased expenses, Akebia expects its cash resources and revenues to fund operations for at least two years.
Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Akebia Therapeutics Inc is anticipated to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through a TradingView subscription.
Two New Akebia Hires Get Stock Options With 4-Year Vesting
Akebia Therapeutics (Nasdaq: AKBA) granted stock options for an aggregate of 61,000 shares to two new employees on July 31, 2026. These inducement awards, granted under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.32 per share and will vest over four years, subject to continued employment. This move aims to incentivize and retain key talent within the biopharmaceutical company focused on kidney disease.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA) reported granting options to purchase 61,000 shares of common stock to two new employees on July 31, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.32 per share. The options vest over four years, with 25% vesting after the first year and the remainder vesting quarterly thereafter, contingent on continued employment.
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has initiated a Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to assess the safety, efficacy, and pharmacokinetics of ebribafusp, which is designed to inhibit complement activation in tissues without affecting the complement system in the blood, potentially offering a safer long-term treatment option. Initial data from the trial, which will enroll up to 30 patients, are expected in 2027.
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has initiated an open-label Phase 2 basket trial to evaluate ebribafusp, a next-generation complement inhibitor, for rare complement-mediated kidney diseases including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial will assess the safety, efficacy, and pharmacokinetics of weekly subcutaneous dosing of ebribafusp, which is designed to inhibit complement activation in tissues without affecting the complement system in the blood. Initial data from the trial, expected to enroll up to 30 patients, is anticipated in 2027.
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript
This article provides the transcript for Akebia Therapeutics Inc.'s Q1 2026 earnings call, held on May 7, 2026. The call began with an introduction by an unidentifed speaker, followed by Mercedes Carrasco. The transcript details the proceedings of the financial results conference call, including a question-and-answer session for participants.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies three promising penny stocks for investors to watch: Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP). It provides a brief financial overview of each company, highlighting their market capitalization, revenue, and key financial challenges or strategic initiatives. While acknowledging the inherent risks of penny stocks, the analysis points to potential growth areas and current financial health ratings for each.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP) as promising penny stocks to watch, despite challenges like unprofitability and high debt. It provides an overview of each company's financial health, operations, and recent developments. The article emphasizes that while these stocks offer affordability and growth potential, they also come with risks typical of smaller or newer companies.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies Akebia Therapeutics, GoodRx Holdings, and Snap Inc. as promising penny stocks, analyzing their financial health and recent developments. While all three companies face challenges like unprofitability or high debt, they also exhibit growth potential and strategic initiatives. The piece emphasizes that penny stocks offer affordability and growth potential but require careful examination of financials.
Akebia Therapeutics And 2 Promising Penny Stocks To Watch
This article identifies Akebia Therapeutics (AKBA), GoodRx Holdings (GDRX), and Snap (SNAP) as promising penny stocks to watch, despite their current unprofitability and financial challenges. It highlights their market caps, revenues, recent developments, and financial health, noting their potential for growth alongside inherent risks. The analysis emphasizes that these stocks offer a mix of affordability and growth potential when supported by strong financials.
Akebia Therapeutics (AKBA) to Announce Earnings on Thursday
Akebia Therapeutics (AKBA) is scheduled to announce its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting a loss of ($0.03) per share and revenue of $48.8520 million. The bi
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics will announce its second quarter 2026 financial results. The company will also hold a conference call and webcast to discuss these results and provide an update on recent business developments.
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced it will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call on the same day at 4:30 p.m. EDT to discuss these results and recent business highlights. A live webcast of the call will be available on the Investors section of Akebia’s website.
Akebia Therapeutics, Inc. Revenue Breakdown – BX:AX9
Akebia Therapeutics, Inc. (BX:AX9) generated 187.25 million CHF last year, with its Innovative Therapeutics segment being the top performer. All of this revenue came from the United States market, indicating a focused geographic revenue stream. This represents an increase from 145.48 million CHF the previous year.
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. The company will also host a conference call on the same day at 4:30 p.m. EDT to discuss these results and recent business highlights. Interested parties can access the call via phone or live webcast.
Akebia plans Aug. 5 webcast after markets close to discuss results
Akebia Therapeutics (Nasdaq: AKBA) will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The company will host a conference call at 4:30 p.m. EDT on the same day to discuss the results and recent business highlights, accessible by phone or webcast. Historical earnings-date reactions for Akebia have been nonnegative, with an average move of 0.72% in the 24 hours following announcements.
AKBA|Akebia Therapeutics Inc|Price:1.275|Chg%:-0.005
Akebia Therapeutics Inc (AKBA) has a healthy fundamental outlook and high growth potential, with its valuation considered fairly valued. Despite strong analyst ratings with a "Strong Buy" consensus and a high institutional ownership, the stock is currently trading sideways. The company is a biopharmaceutical firm focused on kidney disease treatments, with two commercial products, Auryxia and Vafseo, and has shown steady revenue growth averaging 21.36% year-on-year over the past three years.
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Akebia Therapeutics Inc (AKBA), specifically focusing on its business segments, regional revenue, and profit contribution. However, it explicitly states that the relevant data for these breakdowns have not yet been disclosed by the company.
Akebia Therapeutics Inc (AKBA) Income Statement
This article provides the quarterly and annual income statement for Akebia Therapeutics Inc (AKBA), offering detailed financial data such as total revenue, operating expenses, special income, and net income stretching back to FY2012Q4. It highlights the company's financial performance, including a fiscal year 2025 revenue of $236.20M and net income of -$5.34M. The page also includes FAQs explaining how to interpret income statements and key metrics for analyzing AKBA stock.
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Akebia Therapeutics Inc's (AKBA) stock performance, market capitalization, and dividend history. It highlights that the company has not distributed any dividends over the past five years. The page also offers general financial data and company information for AKBA.
AKBA|Akebia Therapeutics Inc|Price:1.220|
This article provides a detailed financial summary of Akebia Therapeutics Inc (AKBA), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, net margin, gross margin, and debt-to-asset ratio, especially focusing on quarterly and annual performance up to FY2026Q1. The company's latest earnings released on May 7, 2026, show an EPS of -0.03 and revenue of 53.54M, with analysts rating it a "STRONG BUY."
